Interface Laboratories

Leadership

David Haslam, MD

Chief Executive Officer

Dr. Haslam brings over 30 years of experience in infectious disease research and pharmaceutical development. His work on novel antifungal compounds has been recognized with multiple industry awards.

Ching-Fang Chang, PhD

Chief Scientific Officer

Dr. Chang leads our research and development initiatives, bringing expertise in molecular genetics, cell biology, microbiology and molecular diagnostics from her previous role as Director of Gli3-Sufu mediated Craniofacial Disease Research at a leading research institution.

Lord Thomas Haslam, Esq.

Chief Operations Officer

Thomas grew up hanging out in research labs playing with dry ice. He went on to obtain a business degree at the University of British Columbia and has more than 10 years experience in marketing and partnerships.

Research Team

James Wilson, PhD

Lead Researcher, Antifungal Program

Specializing in medicinal chemistry, Dr. Wilson leads our efforts to develop novel compounds targeting resistant fungal pathogens.

Lisa Thompson, MD PhD

Lead Researcher, C. difficile Program

With extensive expertise in gut microbiome research, Dr. Thompson directs our initiatives to develop microbiome-sparing treatments for C. difficile infection.

David Kim, PhD

Lead Researcher, Therapeutic Monitoring

Dr. Kim brings expertise in pharmacokinetics and computational modeling to lead our therapeutic drug monitoring program.

Join Our Team

Interface Laboratories is always looking for talented researchers, scientists, and professionals who are passionate about making a difference in infectious disease treatment. Check our careers page for current openings or send your resume to careers@interface-labs.com.